CK Hutchison Holdings Azioni (OTC: CKHUY)

Ultime notizie per CK Hutchison Holdings (OTC:CKHUY) Azioni

CK Hutchison Holdings, or CKH, is a Hong Kong headquartered conglomerate with key businesses in ports, retail, infrastructure, and telecommunications. The company was created in 2015 to house the merged assets of Cheung Kong Holdings and Hutchison Whampoa as the group sought to flatten out and simplify its original holding structure. CKH contains most of the businesses previously housed in Hutchison Whampoa, minus the property assets, which were spun off into their own listing, CK Asset Holdings. Telecommunications and infrastructure activities now make up the largest share of EBITDA, at around 53%. The planned sale of most of the ports business is currently being scrutinized by the government.

CK HUTCH HLD LTD UNSP/ADR by CK Hutchison Holdings LTD

CK Hutchison Holdings Ltd

RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) will release earnings results for the first quarter, after the closing <a href="https://www.benzinga.com/quote/rh/earnings">bell on Thursday, June 12</a>.
Analysts expect the Corte Madera, California-based company to report quarterly loss at 7 cents per share, versus a year-ago loss of 40 cents per share. RH projects to report quarterly revenue at $818.57 million, compared to $726.96 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 20, RH named Lisa Chi as President and Co-Chief Merchandising &amp; Creative Officer.
RH shares fell 5.5% to close at $178.98 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/RH/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Zachary Fadem maintained an Overweight rating and cut the price target from $300 to $250 on June 9, 2025. This analyst has an accuracy rate of 84%.</li>
<li>UBS analyst Michael Lasser maintained a Neutral rating and cut the price target from $235 to $215 on June 5, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Goldman Sachs analyst Kate McShane maintained a Neutral rating and cut the price target from $276 to $194 on May 5, 2025. This analyst has an accuracy rate of 67%.</li>
<li>JP Morgan analyst Christopher Horvers maintained an Overweight rating and slashed the price target from $510 to $250 on April 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Overweight rating and cut the price target from $530 to $300 on April 3, 2025. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying RH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/RH/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-1024x583.png" alt="" class="wp-image-947229" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12041119/image-179.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Analyst Ratings

Trading Ideas

RH Likely To Report Narrower Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

As of June 12, 2025, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a> 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Caseys General Stores Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>)</h3>
<ul class="wp-block-list">
<li>On June 9, Caseys General Stores reported better-than-expected fourth-quarter financial results and increased its quarterly dividend. "Inside same-store sales outperformed the industry, up 2.6%, or 7.1% on a two-year stack basis, led by strong performance in hot sandwiches and bakery as well as alcoholic and non-alcoholic beverages. Our fuel team grew market share and produced a healthy margin, as fuel gross profit increased 10.7% from the prior year," said Darren Rebelez, president and CEO of Casey's General Stores. The company's stock jumped around 14% over the past month and has a 52-week high of $509.08.</li>
<li>RSI Value: 74.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CASY Price Action: Shares of Caseys General Stores gained 1.9% to close at $499.53 on Wednesday.</li>
<li>Edge Stock Ratings: 89.51 Momentum score with Value at 53.81. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/CASY"><img loading="lazy" decoding="async" width="436" height="197" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12072712/image-186.png" alt="" class="wp-image-947474" style="width:308px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12072712/image-186.png 436w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12072712/image-186-300x136.png 300w" sizes="(max-width: 436px) 100vw, 436px" /></a></figure>
<h3 class="wp-block-heading">elf Beauty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>)</h3>
<ul class="wp-block-list">
<li>On May 28, e.l.f. Beauty reported better-than-expected quarterly results and announced it will acquire Rhode. "In this dynamic environment, we continue to deliver industry-leading results. In Fiscal 2025, we grew net sales 28%, gained 190 basis points of market share in the U.S. and continued our international expansion strategy," said Tarang Amin, chairman and CEO of e.l.f. Beauty. The company's stock gained around 68% over the past month and <a href="https://www.benzinga.com/quote/ELF">has a 52-week high</a> of $219.77.</li>
<li>RSI Value: 88.1</li>
<li>ELF Price Action: Shares of elf Beauty gained 5.6% to close at $124.52 on Wednesday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Markets

CASY

Top 2 Defensive Stocks That May Keep You Up At Night In Q2

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Thursday.
Shares of Oxford Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) fell sharply in today's pre-market trading as the company reported in-line earnings for the first quarter and issued second-quarter earnings guidance below estimates. Also, the company <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45877826/oxford-industries-likely-to-report-lower-q1-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">lowered its FY25 guidance.</a>
Oxford Industries posted adjusted EPS of $1.82, in-line with estimates. The company's quarterly sales came in at $392.86 million versus expectations of $384.77 million.
Oxford Industries shares dipped 10.1% to $44.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) dipped 17% to $31.32 in pre-market trading. Tonix Pharmaceuticals may sell up to $150 million in common stock.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell 12.4% to $24.97 in pre-market trading after the company announced a $1.75 billion proposed private offering of convertible senior notes.</li>
<li>Karooooo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) dipped 11.1% to $52.94 in pre-market trading.</li>
<li>Yiren Digital Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) declined 10.1% to $6.69 in pre-market trading.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 9.9% to $10.87 in pre-market trading.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 8.6% to $24.00 in pre-market trading.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 7.4% to $198.10 in pre-market trading. An Air India Boeing 787-8 Dreamliner by Boeing crashed on Thursday near the India's Ahmedabad airport, with 242 passengers on board. The flight was en route to London Gatwick from Ahmedabad.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) fell 4.4% to $234.57 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Movers

DFDV

KARO

TNXP

Oxford Industries, GameStop, Boeing And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care
HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#NYSE">VNRX</a>) ("Volition"), a multi-national epigenetics company, today announced <a href="https://ccforum.biomedcentral.com/articles/10.1186/s13054-025-05415-6#citeas">the publication of a new clinical manuscript</a>&nbsp;suggesting that the Nu.Q&#xAE; H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and subphenotypes.
About the Study This study aimed to evaluate H3.1 nucleosomes in critical illness, assessing their relationship with sepsis, organ failure, inflammatory subphenotypes and outcomes.
The MARS cohort was used, comprising of consecutive Intensive Care Unit patients (n=1713 patients), with plasma samples collected on days 0, 2 and 4 (n=3671 plasma samples).
H3.1 nucleosome concentrations were measured using the Nu.Q&#xAE; NETs Immunoassay at baseline and longitudinally.
The relationship between H3.1 nucleosome concentrations and clinical outcomes was investigated.

VNRX

VolitionRx Announces Publication Of New Clinical Manuscript Suggesting That Nu.Q H3.1 Biomarker Has Potential To Inform Clinical Care In Critically-Ill ICU Patients In Assessment Of Sepsis, Organ Failure And Subphenotypes

Contracts

Eaton Awarded Multiple Contracts Valued At $25M For Hartsfield-Jackson Atlanta International Airport

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst David Manthey initiated coverage on QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) with an Outperform rating and announced a price target of $32. QXO shares closed at $19.95 on Wednesday. <a href="https://www.benzinga.com/quote/qxo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Yasmeen Rahimi initiated coverage on Tvardi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) with an Overweight rating and announced a price target of $78. Tvardi Therapeutics shares closed at $26.22 on Wednesday. <a href="https://www.benzinga.com/quote/tvrd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth Capital analyst Joe Reagor initiated coverage on AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) with a Buy rating and announced a price target of $52. Anglogold Ashanti shares closed at $45.87 on Wednesday. <a href="https://www.benzinga.com/quote/AU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Texas Capital Securities analyst David Bain initiated coverage on Genius Sports Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Buy rating and announced a price target of $14. Genius Sports shares closed at $9.66 on Tuesday. <a href="https://www.benzinga.com/quote/GENI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst David Tarantino initiated coverage on Modine Manufacturing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) with an Overweight rating and announced a price target of $125. Modine Manufacturing shares closed at $94.15 on Wednesday. <a href="https://www.benzinga.com/quote/MOD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MOD stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Initiation

GENI

TVRD

This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Tempus AI To Collaborate With The Abrams Research Center On Neurogenomics At Northwestern University Feinberg School Of Medicine To Harness AI For Discovery in Alzheimer's Research

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announces that its Board of Directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. The proposed action remains subject to approval by Nasdaq and, if approved, the Company will issue a subsequent announcement disclosing the effective date.
At the effective time of the reverse stock split, every 25 shares of the Company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock. This will reduce the number of issued and outstanding shares of common stock from 26,210,037 shares to approximately 1,048,401 shares, without giving effect to rounding. The split will also apply to Company common stock issuable upon the exercise of the Company's outstanding RSU grants and warrants. No fractional shares will be issued; instead, any fractional entitlements will be rounded up to the next highest whole number at the participant level.
The reverse stock split is part of Shuttle's strategic plan to maintain compliance with Nasdaq's continued listing requirements, while also strengthening the Company's long-term capital structure.

Stock Split

SHPH

Shuttle Pharma Board Approves Proposed Reverse Stock Split Of Common Stock At Ratio Of 25-For-1

WIIM

SOAR

Volato Group shares are trading higher after the company announced it signed a non-binidng term sheet to acquire M2i Global.

BLIN

Bridgeline Digital Renews Engagement With Global Water Technology Provider To Optimize Online Presence Of One Of Its Flagship Brands

Micron Plans To Invest Approximately $200B In Semiconductor Manufacturing And R&D In Idaho, New York And Virginia; Will Build A Memory Manufacturing Fab In Idaho And Expand Virginia Fab

Management

STRL

Sterling Infrastructure Appoints Nicholas Grindstaff As CFO, Effective July 10, 2025

ALLE

Allegion To Acquire ELATEC For €330M On A Cash-Free And Debt-Free Basis

Guidance

SAGT

Sagtec Global Projects FY25 Net Income To Be ~$2.56M Vs $1.60M Last Year, Up 60% Yoy

Needham analyst Mike Matson downgrades Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) from Buy to Hold and maintains the price target from $61 to $61.

Downgrades

CNMD

Needham Downgrades Conmed to Hold, Maintains Price Target to $61

Buybacks

IMAX

IMAX Announces $100M Increase To Its Current Share Repurchase Program

Sagtec Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) ("Sagtec" or the "Company"), a next-generation provider of customizable AI, robotics, and automation platforms, today issued financial guidance for the fiscal year ending December 31, 2025. The Company is forecasting FY2025 revenue of approximately US$22.3 million, a 92% year-over-year increase compared to US$11.6 million in FY2024.

Sagtec Global Expects FY25 Revenue Of ~$22.3M Vs $11.6M In FY2024, Up 92% YoY

Macro Economic Events

Econ #s

Economics

Core PPI (YoY) (May) +3% vs +3.1% Est.

Macro Notification

General

USA Initial Jobless Claims 248K Vs 242K Est.

USA PPI (MoM) For May 0.1% Vs 0.2% Est.

CK Hutchison Holdings

Comments

CK Hutchison Holdings

Notizie

Ultime notizie per CK Hutchison Holdings (OTC:CKHUY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO